Key Takeaways Novartis to acquire Excellergy for up to $2B, adding Exl-111 to expand its IgE-focused pipeline.NVS strengthens allergy franchise with next-gen anti-IgE therapy targeting food allergy and asthma.Deal aligns with immunology push as Novartis advances pipeline amid patent and generic pressures.Novartis (NVS) has announced the proposed acquisition of Excellergy Inc., reinforcing its strategic focus on expanding its immunology pipeline, particularly in food allergy and other IgE-mediated diseases.E ...